Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:NXL

Nexalin Technology Q4 2025 Earnings Report

Nexalin Technology logo
$0.45 -0.05 (-10.27%)
Closing price 06/9/2026 04:00 PM Eastern
Extended Trading
$0.48 +0.04 (+7.78%)
As of 07:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nexalin Technology EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Nexalin Technology Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.08 million
Beat/Miss
Beat by +$91.90 thousand
YoY Revenue Growth
N/A

Nexalin Technology Announcement Details

Quarter
Q4 2025
Date
3/25/2026
Time
Before Market Opens
Conference Call Date
Wednesday, March 25, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Nexalin Technology's Q4 2025 Annual reportAnnual report
(10-K)

Nexalin Technology Earnings Headlines

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306897/0/en/nexalin-technology-announces-issuance-of-u-s-patent-covering-dynamic-frequency-stimulation-for-anxiety-depression-and-insomnia.html
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research ...
May 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nexalin-technology-secures-key-neurostimulation-legislative-provision-commends-u-s-house-passed-report-language-expanding-non-invasive-deep-brain-neurostimulation-research-at-the-department-of-1036183306
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.tc pixel
June 10 at 1:00 AM  |  Behind the Markets (Ad)
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299313/0/en/nexalin-technology-secures-key-neurostimulation-legislative-provision-commends-u-s-house-passed-report-language-expanding-non-invasive-deep-brain-neurostimulation-research-at-the-d.html
Nexalin Technology, Inc.: Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial
May 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68536457-nexalin-technology-inc-nexalin-acquires-ai-integrated-digital-health-platform-behind-halo-clarity-and-nexalin-neurocare-ahead-of-planned-fda-pivota-399.htm
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297478/0/en/nexalin-acquires-ai-integrated-digital-health-platform-behind-halo-clarity-and-nexalin-neurocare-ahead-of-planned-fda-pivotal-trial.html
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL) is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions.

Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.

View Nexalin Technology Profile
Earnings Tools